Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Affimed N.V. (AFMD)

Affimed N.V. (AFMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Affimed N.V. GOTTLIEB-DAIMLER-STRASSE 2 MANNHEIM 2M 68165 DEU

www.affimed.com P: 49-62-15600-30 F: 221-674-3649

Description:

Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.

Key Statistics

Overview:

Market Capitalization, $K 78,419
Enterprise Value, $K 49,869
Shares Outstanding, K 15,227
Annual Sales, $ 8,960 K
Annual Net Income, $ -114,660 K
Last Quarter Sales, $ 460 K
Last Quarter Net Income, $ -21,770 K
EBIT, $ -115,440 K
EBITDA, $ -113,550 K
60-Month Beta 2.05
% of Insider Shareholders 3.80%
% of Institutional Shareholders 30.82%
Float, K 14,648
% Float 96.20%
Short Volume Ratio 0.42

Growth:

1-Year Return -41.15%
3-Year Return -95.32%
5-Year Return -85.51%
5-Year Revenue Growth -68.03%
5-Year Earnings Growth -101.84%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.70 on 11/14/23
Latest Earnings Date 05/28/24
Earnings Per Share ttm -6.20
EPS Growth vs. Prev Qtr 22.73%
EPS Growth vs. Prev Year -54.55%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 03/11/24

AFMD Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -118.17%
Return-on-Assets % -81.35%
Profit Margin % -1,279.69%
Debt/Equity 0.21
Price/Sales 8.62
Price/Cash Flow N/A
Price/Book 1.21
Book Value/Share 4.19
Interest Coverage -4.30
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar